Company news

Lexicon Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

June 18, 2024

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

June 17, 2024

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

June 13, 2024

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

May 28, 2024

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

May 13, 2024

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

May 8, 2024

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

April 28, 2024

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

April 28, 2024

Lexicon Pharmaceuticals to Host 2024 Investor Day

April 17, 2024

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

March 24, 2024

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

March 11, 2024

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

March 10, 2024

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

March 10, 2024

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

March 10, 2024

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

December 20, 2023

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

November 29, 2023

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

November 11, 2023

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

November 9, 2023

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 7, 2023

Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023

November 2, 2023

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023

November 1, 2023

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

October 31, 2023

Lexicon Strengthens Management Team With Two New Executives

October 30, 2023

New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting

October 29, 2023

Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

October 16, 2023

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

October 10, 2023

Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer

October 8, 2023

INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients

October 8, 2023

Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

September 27, 2023

Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

September 25, 2023

Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference

September 6, 2023

Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

September 6, 2023

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

August 20, 2023

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

August 7, 2023

Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023

Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

July 27, 2023

Lexicon Elects Diane E. Sullivan to Board of Directors

July 27, 2023

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

June 22, 2023

Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions

June 19, 2023

UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

June 14, 2023

Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference

June 5, 2023

Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares

June 4, 2023

Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement

May 31, 2023

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

May 25, 2023

New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure

May 9, 2023

Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.